ПАТОГЕНЕЗ, ПРОФИЛАКТИКА И ВЕДЕНИЕ БОЛЬНЫХ С АНЕМИЕЙ, ВОЗНИКАЮЩЕЙ НА ФОНЕ ПРОТИВОВИРУСНОЙ ТЕРАПИИ ХРОНИЧЕСКОГО ГЕПАТИТА С С ПРИМЕНЕНИЕМ БОЦЕПРЕВИРА
Номер журнала:
7
Год издания:
2015
При современной «тройной» противовирусной терапии хронического гепатита С с применением ингибитора вирусной протеазы I поколения 1-й волны боцепревира частота развития анемии, в том числе тяжелой, выше, чем при «двойной» терапии пегилированным интерфероном и рибавирином; при этом снижение гемоглобина выражено больше и развивается раньше. Обсуждаются: современные представления о патогенезе анемии; факторы риска ее развития; оптимальные на сегодня подходы к ее прогнозированию, профилактике, ведению больных хроническим гепатитом С, получающих «тройную» противовирусную терапию с применением боцепревира.
Ключевые слова:
хронический гепатит С
противовирусная терапия
ингибитор протеазы I поколения 1-й волны боцепревир
анемия
эритропоэтин
снижение дозы рибавирина
Для цитирования
Бурневич Э., Тихонова Н. ПАТОГЕНЕЗ, ПРОФИЛАКТИКА И ВЕДЕНИЕ БОЛЬНЫХ С АНЕМИЕЙ, ВОЗНИКАЮЩЕЙ НА ФОНЕ ПРОТИВОВИРУСНОЙ ТЕРАПИИ ХРОНИЧЕСКОГО ГЕПАТИТА С С ПРИМЕНЕНИЕМ БОЦЕПРЕВИРА
. Врач, 2015; (7): 12-18 Список литературы:
- Ghany M., Nelson D., Strader D. et al. Genotype 1 HCV treatment guidelines // Hepatology. – 2011; 54: 1433–44.
- Poordad F., McCone J., Bacon B. et al. Boceprevir for untreated chronic HCV genotype 1 infection // N. Engl. J. Med. – 2011; 364: 1195–206.
- Bacon B., Gordon S., Lawitz E. et al. Boceprevir for previously treated chronic HCV genotype 1 infection // N. Engl. J. Med. – 2011; 364: 1207–17.
- Ребетол®. Инструкция по медицинскому применению.
- Sulkowski M., Shiffman M., Afdhal N. et al. Treatment-Related Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon. Ribavirin: Results From the IDEAL Study / AASLD, 2008.
- Romero-Gomez M., Berenguer M., Molina E. et al. Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations // J. Hepatol. – 2013; 59 (6): 1323–30.
- Ramachandran P., Fraser A., Agarwal K. et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients // Aliment. Pharmacol. Ther. – 2012; 35 (6): 647–62.
- Teixeira R., Nascimento Yde A., Crespo D. Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions // Braz. J. Infect. Dis. – 201; 17 (2): 194–204.
- McHutchison J., Lawitz E., Shiffman M. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection // N. Engl. J. Med. – 2009; 36: 580–9.
- Adiwijaya B., Kieffer T., Adda N. et al.: Quantification the effect of adherence to clinical outcomes in telaprevir-based regimens. HepDART, 2011, Poster 53.
- Sulkowski M., Reddy K., Pedicone L. et al. ITPA Deficiency is Associated with Lower Rates of Anemia and EPO use in Patients Treated with Boceprevir (BOC) plus Peginterferon/Ribavirin (PR) / AASLD, 2011.
- Sulkowski M., Poordad F., Manns M. et al. Anemia During Treatment With Peginterferon Alfa-2b/Ribavirin With or Without Boceprevir is Associated With Higher SVR Rates: Analysis of Previously Untreated and Previous Treatment-Failure Patients / EASL, 2011.
- Poordad F., Lawitz E., Reddy K. et al. Timing and Magnitude of Ribavirin Dose Reduction do not impact SVR with Boceprevir + Peginterferon. Ribavirin in the Anemia Management Study in HCV G1 Patients / AASLD, 2012.
- Poordad F., Lawitz E., Reddy K. et al. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis С receiving boceprevir plus peginterferon/ribavirin / EASL, 2012.
- Poordad F., Lawitz E., Reddy K. et al. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection a randomized trial // Gastroenterology. – 2013; 145 (5): 1035–44.
- Hezode C., Dorival C., Zoulim F. et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders: first results of the French early access program (ANRS CO20-CUPIC) / EASL, 2012.
- Franceschi L., Fattovich G., Turrini F. et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage // Hepatology. – 2000; 31: 997–1004.
- Hezode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice // Liver Int. – 2012; 32 (Suppl. 1): 32–8.
- Peck-Radosavljevic M., Wichlas M., Homoncik-Kraml M. et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha // Gastroenterology. – 2002; 123: 141–51.
- Sulkowski M., Poordad F., Manns M. et al. Anemia during treatment with peginterferon alfa-2b/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment-failure patients // J. Hepatol. – 2011; 54 (Suppl. 1): 195–6.
- Hezode C., Fontaine H., Dorival C. et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890 // J. Hepatol. – 2013; 59 (3): 434–41.
- Butt A., McGinnis K., Skanderson M. et al. Hepatitis C treatment completion rates in routine clinical care // Liver Int. – 2010; 30: 240–50.
- EASL Clinical Practice Guidelines: management of hepatitis C virus infection // J. Hepatol. – 2011; 55 (2): 245–64.
- Sulkowski M., Poordad F., Manns M. et al. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial // Hepatology. – 2013; 57 (3): 974–84.
- Fellay J., Thompson A., Ge D. et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C // Nature. – 2010; 464 (7287): 405–8.
- Naggie S., Rallon N., Benito J. et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes // J. Infect. Dis. – 2012; 205: 376–83.
- Nishimura T., Osaki R., Shioya M. et al. Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients // Mol. Med. Report. – 2012; 5: 517–20.
- Thompson A., Fellay J., Patel K. et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction // Gastroenterology. – 2010; 139 (4): 1181–9.
- Rau M., Stickel F., Russmann S. et al. Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection // J. Hepatol. – 2013; 58 (4): 669–75.
- Aghemo A., Degasperi E., Colombo M. Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials // Dig. Liver Dis. – 2013; 45 (1): 1–7.
- Ochi H., Maekawa T., Abe H. et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy – a genome-wide study of Japanese HCV virus patients // Gastroenterology. – 2010; 139 (4): 1190–7.
- Suzuki F., Suzuki Y., Akuta N. et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir // Hepatology. – 2011; 53 (2): 415–21.
- Sulkowski M., Shiffman M., Afdhal N. et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate // Gastroenterology. – 2010; 139 (5): 1602–11.
- McHutchison J. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care // Liver Int. – 2011; 31 (Suppl. 1): 29–35.
- McHutchison J., Lawitz E., Shiffman M. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection // N. Engl. J. Med. – 2009; 36: 580–9.
- Reddy K., Shiffman M., Morgan T. et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment // Clin. Gastroenterol. Hepatol. – 2007; 5 (1): 124–9.
- Shiffman M., Ghany M., Morgan T. et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C // Gastroenterology. – 2007; 132: 103–12.
- Reddy K., Nelson D., Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C // J. Hepatol. – 2009; 50 (2): 402–11.
- Hezode C., Forestier N., Dusheiko G. et al. Telaprevir and peg-interferon with or without ribavirin for chronic HCV infection // N. Engl. J. Med. – 2009; 360: 1827–38.
- Kwo P., Lawitz E., McCone J. et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatmentnaпve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicenter phase 2 trial // Lancet. – 2010; 376: 705–16.